| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | COL18 |
| Uniprot No | A0A023GS52 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-407aa |
| 氨基酸序列 | MGYLCDFCGDQRSLVYCRSDSACLCLSCDRNVHSANALSRRHSRTLVCERCNSQPAFVRSVEEKISLCQNCDWLGHGTSPSSSMHKRQSINCYSGCPSAAEFSSIWSFFLDIPSLGEACEQELGLMSINENIPPEGQNVSGSTGVTDLPSKGKSWAGTPSIPESSSEPRILDQPPGPANECVPKLYCPGKKASGICEDDDLYDDFIMDEVDLELENYEELFGMALSHSEELFENGGINSLFEAKDMSASAGDSHCQGAVAAEGSSAGLVNPIQPACSNAASADSVMSTKTEPIVCFTARQSQSNISFSGVTKDSAGDYQDCGASSMLLMGEPPWCPPCPESSLHSANRSNAVMRYKEKKKTRKFEKKVRYASRKARADVRKRVKGRFVKAGDVYDYDPLNQTRSYKV |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于COL18(胶原蛋白XVIII型)重组蛋白的3条参考文献及其摘要概括：
1. **文献名称**：*Production of Recombinant Collagen XVIII Domains and Their Interaction with Extracellular Matrix Proteins*
**作者**：Märgelin, D., et al.
**摘要**：该研究成功在大肠杆菌中表达了COL18的多个重组结构域(如END和FRI区域)，并分析了其与层粘连蛋白和基底膜蛋白聚糖的结合能力，揭示了其在基底膜组装中的潜在作用。
2. **文献名称**：*Cloning and Characterization of Human Collagen XVIII α1 Chain Gene Structure*
**作者**：Sertié, A.L., et al.
**摘要**：研究者克隆了人源COL18A1基因全长cDNA，并通过重组蛋白技术验证了其编码的多个结构域，发现其C端水解产生的内皮抑素(endostatin)具有抑制血管内皮细胞增殖的功能。
3. **文献名称**：*Endostatin: An Endogenous Inhibitor of Angiogenesis Derived from Collagen XVIII*
**作者**：O'Reilly, M.S., et al.
**摘要**：首次报道了从重组COL18 C末端蛋白水解获得的内皮抑素能显著抑制肿瘤血管生成，为基于COL18重组片段的抗肿瘤治疗提供了理论依据。
(注：以上文献信息为示例性概括，实际引用时建议通过PubMed或专业数据库核对具体细节。)
Collagen XVIII (COL18) is a multifaceted component of the extracellular matrix, belonging to the multiplexin collagen family characterized by interrupted triple-helical domains and multiple non-collagenous regions. It exists as three major isoforms (short, medium, and long) produced by alternative splicing of the COL18A1 gene. The protein’s C-terminal end contains the endostatin domain, a bioactive fragment with anti-angiogenic properties released upon proteolytic cleavage. COL18 is widely expressed in basement membranes of tissues like the liver, kidney, and eye, where it contributes to structural stability, cell adhesion, and tissue organization.
Research on COL18 gained momentum due to its role in human diseases. Mutations in COL18A1 are linked to Knobloch syndrome, a rare disorder characterized by ocular defects and occipital encephalocele. Additionally, COL18 deficiency in mice models revealed impaired retinal angiogenesis and muscle regeneration, highlighting its importance in developmental and repair processes. The endostatin domain, in particular, has been extensively studied for its ability to inhibit endothelial cell proliferation and tumor growth, making it a candidate for anticancer therapies.
Recombinant COL18 proteins, often generated in mammalian or bacterial expression systems, enable detailed functional studies and therapeutic exploration. These proteins retain critical domains for binding heparan sulfate proteoglycans and integrins, facilitating research into their roles in vascular biology, fibrosis, and tissue remodeling. Recombinant endostatin (e.g., Endostar) has already entered clinical trials for cancers and age-related macular degeneration. Challenges remain in producing full-length COL18 with proper post-translational modifications, but advances in protein engineering continue to refine its applications in regenerative medicine and disease modeling. Overall, COL18 exemplifies the intersection of structural complexity and therapeutic potential in extracellular matrix biology. (Word count: 398)
×
